Schrödinger (NASDAQ:SDGR) Stock Price Down 2.4% Following Insider Selling

Schrödinger, Inc. (NASDAQ:SDGR - Get Free Report) was down 2.4% on Tuesday after an insider sold shares in the company. The stock traded as low as $25.27 and last traded at $25.89. Approximately 220,644 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 804,539 shares. The stock had previously closed at $26.54.

Specifically, insider Karen Akinsanya sold 16,723 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $25.09, for a total transaction of $419,580.07. Following the transaction, the insider now directly owns 15,625 shares in the company, valued at $392,031.25. The trade was a 51.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. KeyCorp raised their price target on Schrödinger from $30.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday. Piper Sandler dropped their target price on shares of Schrödinger from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $33.00.

Schrödinger Price Performance

The stock has a market cap of $1.88 billion, a PE ratio of -11.00 and a beta of 1.77. The company's fifty day moving average is $22.01 and its 200-day moving average is $21.00.

Schrödinger (NASDAQ:SDGR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The company had revenue of $88.32 million for the quarter, compared to analysts' expectations of $83.20 million. Analysts expect that Schrödinger, Inc. will post -2.37 EPS for the current year.

Hedge Funds Weigh In On Schrödinger

Several institutional investors have recently made changes to their positions in the company. Stanley Laman Group Ltd. grew its position in Schrödinger by 17.3% during the first quarter. Stanley Laman Group Ltd. now owns 186,980 shares of the company's stock valued at $3,691,000 after buying an additional 27,511 shares during the period. Greenwood Capital Associates LLC raised its holdings in Schrödinger by 2.7% in the 1st quarter. Greenwood Capital Associates LLC now owns 23,139 shares of the company's stock worth $457,000 after purchasing an additional 612 shares during the period. GAMMA Investing LLC boosted its position in Schrödinger by 118.5% during the first quarter. GAMMA Investing LLC now owns 6,109 shares of the company's stock worth $121,000 after purchasing an additional 3,313 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Schrödinger by 32.4% in the first quarter. Harbor Capital Advisors Inc. now owns 15,005 shares of the company's stock valued at $296,000 after buying an additional 3,676 shares in the last quarter. Finally, United Advisor Group LLC raised its stake in shares of Schrödinger by 3.3% during the 4th quarter. United Advisor Group LLC now owns 19,769 shares of the company's stock worth $381,000 after buying an additional 634 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.